FDA expanded clearance for O3 monitoring use by Masimo.
2 reports, 2 independent
Updated Jun 28
Gone quiet
- Reports
- 2
- Developments
- 1
- Repetition
- 50%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
FDA expanded clearance for O3 monitoring use by Masimo.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
Related events
- The FDA cleared an Apple Watch monitoring tool that was developed through research conducted at the University of Oxford.
- FDA reviewed protocol amendment and interim safety data for a company's product.
- A study protocol involving a company based in Mont-Saint-Guibert was approved by the U.S. FDA.
- The FDA granted Safe to Proceed for the Pivotal Phase 3 study of Vivace Therapeutics, Inc.
- AOTI Inc.'s therapy received regulatory clearance from the FDA, with the company based in Galway and Oceanside.